Astrazeneca's Shares Tumble 0.84% as Trading Volume Plummets to 259th in Volume Amid EMA Delays and Partnership Uncertainty

Astrazeneca (AZN) closed down 0.84% on October 2, 2025, with a trading volume of $0.46 billion, representing a 62.12% decline from the previous day's activity. The stock ranked 259th in trading volume among listed equities for the session.

The decline followed reports of ongoing delays in the European Medicines Agency's (EMA) review of the company's oncology pipeline. Regulatory uncertainty surrounding key assets has raised investor concerns about potential revenue risks. Separately, Astrazeneca announced a partnership with Moderna to explore combination therapies for solid tumors, though the collaboration remains in early-stage trials.

Analysts noted that the stock's muted performance was also influenced by broader market volatility in healthcare equities. The lack of near-term catalysts, including upcoming data readouts from Phase III trials, has limited short-term upside potential. Institutional investors appear to be adopting a wait-and-see approach ahead of Q4 earnings releases.

To run this back-test properly I need to nail down a couple of practical details: 1. Market universe • Do you want the U.S. stock market (all primary-listed NYSE + NASDAQ issues), or another market? • If another market, please specify the exchange(s). 2. Portfolio construction details • Equal-weight each of the 500 names, or weight by (for example) traded dollar volume? • Rebalancing/transaction timing: buy at the close of day t (when we observe that day’s volume ranking) and sell at the next day’s close, or another convention? 3. Data coverage • Our current back-testing engine is built for single-ticker or single-index analysis. – To replicate a 500-stock daily-rebalanced basket, I can either a) approximate the strategy with an available broad-market index/ETF, or b) export the daily top-500 list to an external file and compute an equal-weighted composite return series, then feed that series into the engine. • Approach (b) is more precise but will take a little extra processing time. Are you happy to proceed with that? Let me know your preferences on the above so I can structure the back-test exactly the way you’d like.